Interim Report January - December 2002

BIOINVENT FINANCIAL STATEMENT 1 JANUARY-31 DECEMBER 2002 q BioInvent is developing drugs against arteriosclerosis and HIV. Acquires rights from prominent research groups in Sweden and the US. q New customers. Three-year agreement with Oxford GlycoSciences (OGS) for development of antibody-based drugs. Other new customers in 2002 include CellControl Laboratories AG and Pharmacia Diagnostics AB. q New agreements for increased cooperation with existing customers. Significant increase in cooperation with GlaxoSmithKline Biologicals, ImmunoGen and Igeneon. q q Net revenue for January - December 2002 increased to SEK 87.1 million (58.3). q Cash flow from current operations and investment activity for January - December 2002: SEK -47.1 million (-74.8). Liquid funds at year end: SEK 343.6 million (338.7). Loss after net financial items for January - December 2002: SEK -46.2 million (-43.5). Contact: Any questions regarding this report will be answered by: Svein Mathisen, President and CEO, +46 (0)46 286 85 67 or Jonas Källmén, CFO, +46 (0)46 286 38 12. The report is also available at www.bioinvent.com BioInvent International AB (publ.) Co. reg. no. 556537-7263 ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00600/wkr0001.doc The full report http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00600/wkr0002.pdf The full report

About Us

BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer. The company has unique expertise in antibody drug development from initial concept to late clinical phase. The antibody library n-CoDeR and the screening tool F.I.R.S.T. are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at www.bioinvent.com.

Subscribe